| EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, J Bellmunt, M Bolla, E Briers, MG Cumberbatch, M De Santis, ... European urology 71 (4), 618-629, 2017 | 3846 | 2017 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 243-262, 2021 | 2619 | 2021 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 263-282, 2021 | 964 | 2021 |
| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 912 | 2018 |
| The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review N Fossati, PPM Willemse, T Van den Broeck, RCN van den Bergh, ... European urology 72 (1), 84-109, 2017 | 553 | 2017 |
| Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ... European urology 75 (6), 967-987, 2019 | 499 | 2019 |
| What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the … PC Moldovan, T Van den Broeck, R Sylvester, L Marconi, J Bellmunt, ... European urology 72 (2), 250-266, 2017 | 430 | 2017 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 402 | 2021 |
| EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer N Mottet, J Bellmunt, E Briers, M Bolla, L Bourke, P Cornford, M De Santis, ... European Association of Urology, 2018 | 385 | 2018 |
| Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review M Lardas, M Liew, RC van den Bergh, M De Santis, J Bellmunt, ... European urology 72 (6), 869-885, 2017 | 291 | 2017 |
| Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology JP Droz, M Aapro, L Balducci, H Boyle, T Van den Broeck, P Cathcart, ... The lancet oncology 15 (9), e404-e414, 2014 | 278 | 2014 |
| EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international … TBL Lam, S MacLennan, PPM Willemse, MD Mason, K Plass, R Shepherd, ... European urology 76 (6), 790-813, 2019 | 249 | 2019 |
| EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology, 2024 | 235 | 2024 |
| Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations T Van den Broeck, RCN van den Bergh, E Briers, P Cornford, ... European urology focus 6 (2), 231-234, 2020 | 208 | 2020 |
| Androgen receptor antagonists for prostate cancer therapy C Helsen, T Van den Broeck, A Voet, S Prekovic, H Van Poppel, S Joniau, ... Endocrine-related cancer 21 (4), T105-T118, 2014 | 175 | 2014 |
| Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ... European urology 77 (5), 614-627, 2020 | 159 | 2020 |
| Emerging mechanisms of enzalutamide resistance in prostate cancer F Claessens, C Helsen, S Prekovic, T Van den Broeck, L Spans, ... Nature reviews urology 11 (12), 712-716, 2014 | 154 | 2014 |
| The effect of F877L and T878A mutations on androgen receptor response to enzalutamide S Prekovic, ME van Royen, ARD Voet, B Geverts, R Houtman, D Melchers, ... Molecular cancer therapeutics 15 (7), 1702-1712, 2016 | 116 | 2016 |
| Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review RCN van den Bergh, NJ van Casteren, T Van den Broeck, ER Fordyce, ... European urology 69 (5), 802-820, 2016 | 116 | 2016 |
| Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants T Dadaev, EJ Saunders, PJ Newcombe, E Anokian, DA Leongamornlert, ... Nature communications 9 (1), 2256, 2018 | 114 | 2018 |
Steven JoniauUrologist, University Hospitals LeuvenVerificeret mail på uzleuven.be